1. Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial.
- Author
-
Jafari S, Ashrafizadeh SG, Zeinoddini A, Rasoulinejad M, Entezari P, Seddighi S, and Akhondzadeh S
- Subjects
- Adult, Anti-Bacterial Agents therapeutic use, Antidepressive Agents adverse effects, Antidepressive Agents pharmacology, Brucellosis drug therapy, Celecoxib adverse effects, Celecoxib pharmacology, Cyclooxygenase 2 Inhibitors adverse effects, Cyclooxygenase 2 Inhibitors pharmacology, Cyclooxygenase 2 Inhibitors therapeutic use, Depression etiology, Double-Blind Method, Female, Humans, Male, Psychiatric Status Rating Scales, Treatment Outcome, Young Adult, Antidepressive Agents therapeutic use, Brucellosis psychology, Celecoxib therapeutic use, Depression drug therapy
- Abstract
What Is Known and Objective: Depression is a debilitating complication of brucellosis and how best to treat this is a matter of debate. Inflammatory processes are involved in the pathogenesis of both brucellosis and depression. Therefore, we hypothesized that celecoxib could be beneficial for the treatment of depression due to brucellosis., Methods: Forty outpatients with depression due to brucellosis with a Hamilton Depression Rating Scale score (HDRS) <19 participated in a randomized, double-blind, placebo-controlled trial and underwent 8 weeks of treatment with either celecoxib (200 mg bid) or placebo as an adjunctive to antibiotic therapy. Patients were evaluated using HDRS at baseline and weeks 4 and 8., Result and Discussion: Repeated-measures analysis demonstrated significant effect for time × treatment interaction on the HDRS score [F (1·43, 57·41) = 37·22, P < 0·001]. Significantly greater response to treatment occurred in the celecoxib group than in the placebo group at the study end [10 patients (50%) vs. no patient (0%), respectively, P < 0·001]. No serious adverse event was observed., What Is New and Conclusion: Celecoxib is a safe and effective treatment for depression due to brucellosis when compared with placebo., (© 2015 John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF